AngioDynamics, initially known as E-Z-EM, was established by founders Eamonn P. Hobbs and Howard S. Stern. The Company focused on developing products for interventional radiologists to use in minimally invasive procedures.

Among the first products developed by AngioDynamics were the Schon Acute Hemodialysis Catheter and the Uni-Fuse Infusion Catheter.

The Company relocated to the “Catheter Valley” in the heart of New York’s Adirondack region.

During this time, AngioDynamics launched several Angiographic Catheter products including, Soft-Vu, OmniFlush, AngiOptic and the Abscession General Drainage Catheter.

In 2004, AngioDynamics became a public company, listing on the Nasdaq. The Company was also listed on the Nasdaq Health Care Index in recognition of its deep commitment to improving patient care.

In this decade, AngioDynamics acquired RITA Medical Systems, which added thermal ablation technologies that enabled the Company to enter the oncology treatment space and was named to Forbes 200 Best Small Companies in America.

AngioDynamics acquires Oncobionic, a company specializing in Irreversible Electroporation (IRE) technology, which brought the noteworthy NanoKnife system. In 2013, AngioDynamics’ ablation and oncology portfolios were created with the acquisition of Microsulis, a company specializing in microwave ablation.

Continued growth led AngioDynamics to move its corporate headquarters to Latham, NY in 2010.

The company made several business and product acquisitions in this decade, including Navilyst Medical, Vortex Medical, Microsulis, Eximo Medical, Ltd., BioSentry, and RadiaDyne and also received 510(k) clearances from the FDA for numerous products.

In January 2018, the FDA granted Expedited Pathway designation for the NanoKnife System and, in April 2019, the FDA approved AngioDynamics’ DIRECT Study on the use of the system for the treatment of Stage III pancreatic cancer.

AngioDynamics’ Auryon Atherectomy System, an innovative technology for the treatment of Peripheral Artery Disease, launched commercially in the United States in 2020. Early that same year, AngioDynamics acquired C3 Wave System, a wireless ECG system, and the third generation of the AngioVac system received a CE Mark.

As part of its growth and transformation, AngioDynamics developed the Scientific & Clinical Affairs department, comprising the company’s global Clinical Affairs and Services, Medical Affairs, Physician Education and Healthcare Economics teams.

The AlphaVac Mechanical Thrombectomy System, an off-circuit, multi-purpose mechanical aspiration thrombectomy device for the non-surgical removal of thrombi or emboli from the vasculature, receives 510(k) clearance from the FDA.

AngioDynamics received approval from the FDA for the Pivotal Study of the NanoKnife System for Ablation of Prostate Tissue in an Intermediate-Risk Patient Population (PRESERVE).

AngioDynamics presented its first invitation-only clinical symposium in March of 2022 in Barcelona, Spain. This International Symposium brought together the foremost experts in the surgery, oncology, urology and vascular fields to discuss the latest clinical learning and explore new and exciting directions for future patient care.

The company also launched a new clinical study assessing the use of its Auryon Atherectomy System in the treatment of calcified lesions in below-the-knee (BTK) arteries. The Acute Pulmonary Embolism Extraction Trial with the AlphaVac System (APEX-AV), a clinical study aimed at evaluating the efficacy and safety of the AlphaVac Multipurpose Mechanical Aspiration (MMA) F18⁸⁵ System in the treatment of acute intermediate-risk pulmonary embolism (PE), was also launched. FDA 510(k) clearance was also granted for an expanded indication of the Auryon Atherectomy System to include arterial thrombectomy.

AngioDynamics announced a partnership with Cardiva, a Spanish-based medical device company, to build upon an existing collaboration between the two, which has seen the successful distribution of AngioDynamics’ vascular access portfolio in Spain and Portugal since 2012.

Patient enrollment was also completed in the Acute Pulmonary Embolism Extraction Trial with the AlphaVac System (APEX-AV). APEX-AV was a clinical study aimed at evaluating the safety and efficacy of the AlphaVac Multipurpose Mechanical Aspiration (MMA) F18⁸⁵ System in the treatment of acute intermediate-risk pulmonary embolism (PE).

AngioDynamics began the year announcing that the FDA cleared the Auryon XL Catheter, a 225-cm radial access catheter, for use with the Auryon Atherectomy System in the treatment of Peripheral Arterial Disease (PAD). In April, the company received 510(k) clearance for AlphaVac F18⁸⁵ System for the treatment of pulmonary embolism (PE), enhancing its utility in critical medical scenarios such as PE.